Northwest Biotherapeutics (NWBO) Notes Payables: 2009-2025
Historic Notes Payables for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to $13.6 million.
- Northwest Biotherapeutics' Notes Payables rose 79.09% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 79.09%. This contributed to the annual value of $14.2 million for FY2024, which is 259.69% up from last year.
- As of Q3 2025, Northwest Biotherapeutics' Notes Payables stood at $13.6 million, which was down 16.81% from $16.3 million recorded in Q2 2025.
- Over the past 5 years, Northwest Biotherapeutics' Notes Payables peaked at $20.0 million during Q3 2022, and registered a low of $2.2 million during Q1 2021.
- Moreover, its 3-year median value for Notes Payables was $10.5 million (2023), whereas its average is $11.2 million.
- Its Notes Payables has fluctuated over the past 5 years, first tumbled by 78.68% in 2021, then skyrocketed by 435.15% in 2022.
- Over the past 5 years, Northwest Biotherapeutics' Notes Payables (Quarterly) stood at $7.1 million in 2021, then surged by 116.82% to $15.4 million in 2022, then plummeted by 74.39% to $3.9 million in 2023, then surged by 259.69% to $14.2 million in 2024, then spiked by 79.09% to $13.6 million in 2025.
- Its Notes Payables was $13.6 million in Q3 2025, compared to $16.3 million in Q2 2025 and $19.6 million in Q1 2025.